Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Oklahoma University Medical Center
mi
from
Oklahoma City, OK
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Oklahoma University Medical Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Lifespan: The Miriam Hospital
mi
from
Providence, RI
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Lifespan: The Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Vermont Cancer Center at University of Vermont
mi
from
Burlington, VT
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Vermont Cancer Center at University of Vermont
mi
from
Burlington, VT
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Martha Jefferson Hospital
mi
from
Charlottesville, VA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Martha Jefferson Hospital
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Virginia Oncology Associates - Norfolk
mi
from
Norfolk, VA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Virginia Oncology Associates - Norfolk
mi
from
Norfolk, VA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
MBCCOP - Massey Cancer Center
mi
from
Richmond, VA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
MBCCOP - Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Oncology and Hematology Associates of Southwest Virginia, Incorporated - Roanoke
mi
from
Roanoke, VA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Oncology and Hematology Associates of Southwest Virginia, Incorporated - Roanoke
mi
from
Roanoke, VA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
St Mary's Medical Center
mi
from
Huntington, WV
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
St Mary's Medical Center
mi
from
Huntington, WV
Click here to add this to my saved trials
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  8/28/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 8/28/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery
Phase II Trial of Single Fraction Radiation Therapy (SFRT) at Roswell Park Cancer Institute for Select Patients With Early Stage Breast Cancer
Status: Enrolling
Updated:  9/2/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery
Phase II Trial of Single Fraction Radiation Therapy (SFRT) at Roswell Park Cancer Institute for Select Patients With Early Stage Breast Cancer
Status: Enrolling
Updated: 9/2/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients
Prospective Study of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients
Status: Enrolling
Updated:  9/3/2015
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients
Prospective Study of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients
Status: Enrolling
Updated: 9/3/2015
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
A Phase 1 Study of Neoadjuvant Chemotherapy With the Gamma Secretase Inhibitor RO4929097 in Combination With Paclitaxel and Carboplatin in Patients With Clinical Stage II-III Triple Negative Breast Cancer
Status: Enrolling
Updated:  9/3/2015
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
A Phase 1 Study of Neoadjuvant Chemotherapy With the Gamma Secretase Inhibitor RO4929097 in Combination With Paclitaxel and Carboplatin in Patients With Clinical Stage II-III Triple Negative Breast Cancer
Status: Enrolling
Updated: 9/3/2015
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Verbal and Written Instruction Versus Verbal and Written Plus Simulation in Patients With Breast Cancer and Their Caregivers
A Comparison of Strategies for Injection Teaching: Verbal and Written Instruction Versus Verbal and Written Plus Simulation in Patients With Breast Cancer and Their Caregivers
Status: Enrolling
Updated:  9/3/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Verbal and Written Instruction Versus Verbal and Written Plus Simulation in Patients With Breast Cancer and Their Caregivers
A Comparison of Strategies for Injection Teaching: Verbal and Written Instruction Versus Verbal and Written Plus Simulation in Patients With Breast Cancer and Their Caregivers
Status: Enrolling
Updated: 9/3/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232)
Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients
Status: Enrolling
Updated:  9/3/2015
University of Maryland/Marlene and Stewart Greenebaum Cancer Center
mi
from
Baltimore, MD
Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232)
Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients
Status: Enrolling
Updated: 9/3/2015
University of Maryland/Marlene and Stewart Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Jonesboro, AR
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Corona, CA
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Corona, CA
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Miami, FL
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Wichita, KA
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Mt Sterling, KY
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Mt Sterling, KY
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Bethesda, MD
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Detroit, MI
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Bismarck, ND
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Bismarck, ND
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Eugene, OR
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Eugene, OR
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Germantown, TN
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Germantown, TN
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Newport News, VA
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Newport News, VA
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Hot Springs, AR
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Fountain Valley, CA
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Riverside, CA
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Riverside, CA
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Evergreen Park, IL
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Evergreen Park, IL
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Park Ridge, IL
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Skokie, IL
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Skokie, IL
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Tucuman,
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Tucuman,
Click here to add this to my saved trials
Interpersonal Therapy for Depression in Breast Cancer
Interpersonal Therapy for Depression in Breast Cancer
Status: Enrolling
Updated:  9/8/2015
New York State Psychiatric Institute
mi
from
New York, NY
Interpersonal Therapy for Depression in Breast Cancer
Interpersonal Therapy for Depression in Breast Cancer
Status: Enrolling
Updated: 9/8/2015
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Anaheim/Orange County
mi
from
Anaheim, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Anaheim/Orange County
mi
from
Anaheim, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente - Deer Valley
mi
from
Antioch, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente - Deer Valley
mi
from
Antioch, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Baldwin Park
mi
from
Baldwin Park, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Baldwin Park
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Bellflower
mi
from
Bellflower, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Bellflower
mi
from
Bellflower, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Fontana
mi
from
Fontana, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Fontana
mi
from
Fontana, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente - Fremont
mi
from
Fremont, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente - Fremont
mi
from
Fremont, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Harbor City
mi
from
Harbor City, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Harbor City
mi
from
Harbor City, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Hayward
mi
from
Hayward, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Hayward
mi
from
Hayward, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente - Irvine
mi
from
Irvine, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente - Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Foundation Hospital - West Los Angeles
mi
from
Los Angeles, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Foundation Hospital - West Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Los Angeles
mi
from
Los Angeles, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente - Ontario Vineyard Medical Offices and Ambulatory SurgiCenter
mi
from
Ontario, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente - Ontario Vineyard Medical Offices and Ambulatory SurgiCenter
mi
from
Ontario, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Redwood City
mi
from
Redwood City, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Redwood City
mi
from
Redwood City, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Richmond
mi
from
Richmond, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Richmond
mi
from
Richmond, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Riverside
mi
from
Riverside, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Riverside
mi
from
Riverside, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Roseville
mi
from
Roseville, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Roseville
mi
from
Roseville, CA
Click here to add this to my saved trials